Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Senti Biosciences (SNTI) Income towards Parent Company (2021 - 2025)

Senti Biosciences has reported Income towards Parent Company over the past 4 years, most recently at -$18.5 million for Q4 2025.

  • For Q4 2025, Income towards Parent Company changed N/A year-over-year to -$18.5 million; the TTM value through Dec 2025 reached -$67.9 million, changed N/A, while the annual FY2025 figure was -$67.9 million, N/A changed from the prior year.
  • Income towards Parent Company for Q4 2025 was -$18.5 million at Senti Biosciences, down from -$16.8 million in the prior quarter.
  • Over five years, Income towards Parent Company peaked at $21.7 million in Q3 2023 and troughed at -$21.7 million in Q2 2022.
  • A 4-year average of -$7.8 million and a median of -$8.8 million in 2021 define the central range for Income towards Parent Company.
  • Biggest five-year swings in Income towards Parent Company: plummeted 997692.87% in 2022 and later skyrocketed 1028.2% in 2023.
  • Year by year, Income towards Parent Company stood at -$3.9 million in 2021, then tumbled by 121.54% to -$8.5 million in 2022, then soared by 99.67% to -$28000.0 in 2023, then crashed by 66110.71% to -$18.5 million in 2025.
  • Business Quant data shows Income towards Parent Company for SNTI at -$18.5 million in Q4 2025, -$16.8 million in Q3 2025, and -$16.5 million in Q2 2025.